NEW YORK, Nov. 29, 2021 /PRNewswire/ -- The patient derived xenograft market size is anticipated to grow by USD 188.19 mn, progressing at a CAGR of 16.66% during the forecast period. This exclusive market forecast report by Technavio covers market scenarios, estimates, and customer behavior.
Read Our Free Sample Report to explore growth opportunities in the patient derived xenograft market.
The market is driven by factors such as the growing demand for personalized medicine, development of immunodeficient rats, and the increasing incidence of lung cancers. However, stringent government guidelines regarding the ethical use of animals in cancer research and the high cost of patient derived xenograft models are expected to reduce the growth potential in the market.
For additional information on the various trends, drivers, and challenges impacting the market, View a Free Sample Report Now
The patient derived xenograft market report provides complete insights on key vendors, including Champions Oncology Inc., Charles River Laboratories International Inc., Experimental Pharmacology and Oncology EPO Berlin Buch GmbH, Hera Biolabs Inc., Oncodesign SA, PerkinElmer Inc., The Jackson Laboratory, UROSPHERE SAS, and WuXi AppTec Co. Ltd.
The market in focus was fragmented in 2020. It is expected to remain the same during the forecast period due to the presence of a significant number of global, regional, and local players in the market. Companies adopt various marketing strategies such as mergers and acquisitions to increase their market share. This is going to increase the completion among vendors during the forecast period. However, high capital investment is required to enter the market. This will restrict the entry of new entrants during the forecast period and thereby decrease rivalry in the market.
The competitive scenario provided in the patient derived xenograft market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.
By application, the market is classified into preclinical drug development and bio marker analysis. The preclinical drug development segment contributes the largest share of the market.
By geography, the market is classified into North America, Europe, Asia, and ROW. North America will have the largest share of the market during the forecast period.
Subscribe to our "Lite Plan" billed annually at USD 3000 to view 3 reports monthly and download 3 reports annually.
Dental Bone Graft Substitutes Market: The dental bone graft substitutes market has been segmented by end-user (dental clinics and hospitals), type (xenografts, allografts, synthetic bone grafts, and DBM), and geography (Europe, North America, Asia, and ROW). Download Free Sample Report
Immunology Market: The immunology market has been segmented by category (immunosuppressants and immuno boosters) and geography (North America, Europe, Asia, and ROW). Download Free Sample Report
Patient Derived Xenograft Market Scope
Growth momentum & CAGR
Accelerate at a CAGR of 16.66%
Market growth 2021-2025
USD 188.19 million
YoY growth (%)
North America, Europe, Asia, and ROW
Performing market contribution
North America at 40%
Key consumer countries
US, Canada, Mexico, Germany, UK, France, China, Japan, and India
Leading companies, competitive strategies, consumer engagement scope
Champions Oncology Inc., Charles River Laboratories International Inc., Experimental Pharmacology and Oncology EPO Berlin Buch GmbH, Hera Biolabs Inc., Oncodesign SA, PerkinElmer Inc., The Jackson Laboratory, UROSPHERE SAS, and WuXi AppTec Co. Ltd.
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View original content to download multimedia:https://www.prnewswire.com/news-releases/patient-derived-xenograft-market-size-to-grow-by-usd-188-19-mn--major-vendors-include-champions-oncology-inc-and-charles-river-laboratories-international-inc--technavio-301432325.html